Am J Psychiatry 160:1396-1404, August 2003
© 2003 American Psychiatric Association
Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol
Jeffrey A. Lieberman, M.D.,
Gary Tollefson, M.D., Ph.D.,
Mauricio Tohen, M.D., Dr.P.H.,
Alan I. Green, M.D.,
Raquel E. Gur, M.D., Ph.D.,
Rene Kahn, M.D., Ph.D.,
Joseph McEvoy, M.D.,
Diana Perkins, M.D., M.P.H.,
Tonmoy Sharma, M.D.,
Robert Zipursky, M.D.,
Hank Wei, Ph.D.,
Robert M. Hamer, Ph.D., and
the HGDH Study Group
OBJECTIVE: Few long-term studies have compared the efficacy and safety of typical and atypical antipsychotic medications directly in patients with a first episode of psychosis who met the criteria for schizophrenia or a related psychotic disorder. This study compared the acute and long-term effectiveness of haloperidol with that of olanzapine in patients with first-episode psychosis in a large, controlled clinical trial. METHOD: Patients with first-episode psychosis (N=263) were randomly assigned under double-blind conditions to receive haloperidol or olanzapine and were followed for up to 104 weeks. Domains measured included psychopathology, psychosocial variables, neurocognitive functioning, and brain morphology and metabolism. This report presents data from clinical measures of treatment response and safety data from the 12-week acute treatment phase. RESULTS: Haloperidol and olanzapine were associated with substantial and comparable baseline-to-endpoint reductions in symptom severity, which did not differ significantly in last-observation-carried-forward analyses. However, in a mixed-model analysis, olanzapine-treated subjects had significantly greater decreases in symptom severity as measured by the Positive and Negative Syndrome Scale total score and negative and general scales and by the Montgomery-Åsberg Depression Rating Scale but not as measured by the Positive and Negative Syndrome Scale positive scale and by the Clinical Global Impression severity rating. Olanzapine-treated patients experienced a lower rate of treatment-emergent parkinsonism and akathisia but had significantly more weight gain, compared with the haloperidol-treated patients. Overall, significantly more olanzapine-treated subjects than haloperidol-treated subjects completed the 12-week acute phase of the study (67% versus 54%). CONCLUSIONS: As expected on the basis of previous studies, both olanzapine and haloperidol were effective in the acute reduction of psychopathological symptoms in this group of patients with first-episode psychosis. However, olanzapine had several relative advantages in therapeutic response. Although the nature of adverse events differed between the two agents, retention in the study was greater with olanzapine. Retention in treatment is important in this patient population, given their risk of relapse. Longer-term results are needed to determine whether treatment with atypical antipsychotics results in superior outcomes for a first episode of schizophrenia.
This article has been cited by other articles:
|
|
|
|
 
L. J. Kalverdijk, H. Tobi, P. B. van den Berg, J. Buiskool, L. Wagenaar, R. B. Minderaa, and L. T. W. de Jong-van den Berg
Use of Antipsychotic Drugs Among Dutch Youths Between 1997 and 2005
Psychiatr Serv,
May 1, 2008;
59(5):
554 - 560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak
Rethinking Antipsychotic Formulary Policy
Schizophr Bull,
March 1, 2008;
34(2):
375 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rabinowitz and O. Davidov
The Association of Dropout and Outcome in Trials of Antipsychotic Medication and Its Implications for Dealing With Missing Data
Schizophr Bull,
March 1, 2008;
34(2):
286 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Leucht, S. Heres, J. Hamann, and J. M. Kane
Methodological Issues in Current Antipsychotic Drug Trials
Schizophr Bull,
March 1, 2008;
34(2):
275 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lewis and J. Lieberman
CATIE and CUtLASS: can we handle the truth?
The British Journal of Psychiatry,
March 1, 2008;
192(3):
161 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov
Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features
Schizophr Bull,
February 26, 2008;
(2008)
sbn005v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ascher-Svanum, A. W. Nyhuis, D. E. Faries, B. J. Kinon, R. W. Baker, and A. Shekhar
Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia
Schizophr Bull,
December 21, 2007;
(2007)
sbm134v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hollis, D. Grayson, L. Forrester, H. Brodaty, S. Touyz, and R. Cumming
Antipsychotic Medication Dispensing and Risk of Death in Veterans and War Widows 65 Years and Older
Am J Geriatr Psychiatry,
November 1, 2007;
15(11):
932 - 941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. M. Bratti, J. M. Kane, and S. R. Marder
Chronic Restlessness With Antipsychotics
Am J Psychiatry,
November 1, 2007;
164(11):
1648 - 1654.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rabinowitz and O. Davidov
A Composite Approach That Includes Dropout Rates When Analyzing Efficacy Data in Clinical Trials of Antipsychotic Medications
Schizophr Bull,
September 29, 2007;
(2007)
sbm107v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. McEvoy, J. A. Lieberman, D. O. Perkins, R. M. Hamer, H. Gu, A. Lazarus, D. Sweitzer, C. Olexy, P. Weiden, and S. D. Strakowski
Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison
Am J Psychiatry,
July 1, 2007;
164(7):
1050 - 1060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.S. Leslie, C.R. Hankey, and M.E.J. Lean
Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review
QJM,
July 1, 2007;
100(7):
395 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.G. Steen, R.M. Hamer, and J.A. Lieberman
Measuring Brain Volume by MR Imaging: Impact of Measurement Precision and Natural Variation on Sample Size Requirements
AJNR Am. J. Neuroradiol.,
June 1, 2007;
28(6):
1119 - 1125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Leucht, R. R. Engel, J. Bauml, and J. M. Davis
Is the Superior Efficacy of New Generation Antipsychotics an Artifact of LOCF?
Schizophr Bull,
January 1, 2007;
33(1):
183 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Robinson, M. G. Woerner, B. Napolitano, R. C. Patel, S. M. Sevy, H. Gunduz-Bruce, J. M. Soto-Perello, A. Mendelowitz, A. Khadivi, R. Miller, et al.
Randomized Comparison of Olanzapine Versus Risperidone for the Treatment of First-Episode Schizophrenia: 4-Month Outcomes
Am J Psychiatry,
December 1, 2006;
163(12):
2096 - 2102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Joober, N. Schmitz, A. Malla, S. Sengupta, and S. Karma
Is olanzapine a brain-sparing medication?
Arch Gen Psychiatry,
November 1, 2006;
63(11):
1292 - 1292.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman
Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
Arch Gen Psychiatry,
October 1, 2006;
63(10):
1069 - 1072.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R Bola
Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?
Schizophr Bull,
April 1, 2006;
32(2):
288 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. I Brixner, Q. Said, P. K Corey-Lisle, A V. Tuomari, G. J L'Italien, W. Stockdale, and G. M Oderda
Naturalistic Impact of Second-Generation Antipsychotics on Weight Gain
Ann. Pharmacother.,
April 1, 2006;
40(4):
626 - 632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Kemmler, M. Hummer, C. Widschwendter, and W. W. Fleischhacker
Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of Antipsychotic Drugs: A Meta-analysis
Arch Gen Psychiatry,
December 1, 2005;
62(12):
1305 - 1312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Zipursky, H. Gu, A. I. Green, D. O. Perkins, M. F. Tohen, J. P. McEvoy, S. M. Strakowski, T. Sharma, R. S. Kahn, R. E. Gur, et al.
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
The British Journal of Psychiatry,
December 1, 2005;
187(6):
537 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Jenkins, M. E. Strauss, E. A. Carpenter, D. Miller, J. Floersch, and M. Sajatovic
Subjective Experience of Recovery from Schizophrenia-Related Disorders and Atypical Antipsychotics
International Journal of Social Psychiatry,
September 1, 2005;
51(3):
211 - 227.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Parellada, R. Andrezina, V. Milanova, P. Glue, M. Masiak, M. St. J. Turner, R. Medori, and W. Gaebel
Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable
J Psychopharmacol,
September 1, 2005;
19(5_suppl):
5 - 14.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. G Robinson, M. G Woerner, H. M Delman, and J. M Kane
Pharmacological Treatments for First-Episode Schizophrenia
Schizophr Bull,
July 1, 2005;
31(3):
705 - 722.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Schooler, J. Rabinowitz, M. Davidson, R. Emsley, P. D. Harvey, L. Kopala, P. D. McGorry, I. Van Hove, M. Eerdekens, W. Swyzen, et al.
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Am J Psychiatry,
May 1, 2005;
162(5):
947 - 953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B Zipursky
Specialised care for early psychosis may reduce number of readmissions
Evid. Based Ment. Health,
May 1, 2005;
8(2):
34 - 34.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman, G. D. Tollefson, C. Charles, R. Zipursky, T. Sharma, R. S. Kahn, R. S. E. Keefe, A. I. Green, R. E. Gur, J. McEvoy, et al.
Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis
Arch Gen Psychiatry,
April 1, 2005;
62(4):
361 - 370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Chakos, S. A. Schobel, H. Gu, G. Gerig, D. Bradford, C. Charles, and J. A. Lieberman
Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia
The British Journal of Psychiatry,
January 1, 2005;
186(1):
26 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. K J Craig, P. Garety, P. Power, N. Rahaman, S. Colbert, M. Fornells-Ambrojo, and G. Dunn
The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis
BMJ,
November 6, 2004;
329(7474):
1067.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Perkins, J. Lieberman, H. Gu, M. Tohen, J. McEvoy, A. Green, R. Zipursky, S. Strakowski, T. Sharma, R. Kahn, et al.
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders
The British Journal of Psychiatry,
July 1, 2004;
185(1):
18 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Ment. Health,
February 1, 2004;
7(1):
3 - 4.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rosack
Psychiatr News,
September 5, 2003;
38(17):
22 - 22.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2003
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
